Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Codexis and Casdin Capital Launch SynBio Innovation Accelerator

Combines Codexis’ R&D and commercialization platform with Casdin Capital’s investment expertise to invest in and support innovative early stage life science and synthetic biology technology companies

Inaugural investment in Arzeda Corp., a next generation protein design company

Accelerator is key component of Casdin’s plans to invest upwards of $50 million into sector

Codexis, a leading Synthetic Biology company developing and supplying differentiated enzyme products for high value markets, in collaboration with leading life science investor Casdin Capital, announce the launch of SynBio Innovation Accelerator. The goal of the accelerator is to fund and nurture early stage companies with disruptive technology platforms or unique product development capabilities in the far reaching and transformative field of synthetic and industrial biotechnology. Casdin Capital envisions in the next several years investing upwards of $50 million into companies tied to the industry and the SynBio Innovation Accelerator.

Related Posts
1 of 31,579

Recommended AI News: AUTOCRYPT Launches C-V2X Solution Demonstrating Interoperability With China C-SCMS Standards

John Nicols, President and CEO of Codexis said, “We are at a tipping point for Synthetic Biology, as the Genomic Revolution transformed our ability to read and translate the blueprint of life, and in the process enabled a second and equally powerful SynBio revolution. Today we have a remarkable ability to not just read DNA but write and engineer transformative biologic products. Codexis’ 20-year history in the space has shown us that it takes more than just capital to deliver differentiated products to the market. Leveraging the company’s proven protein engineering technology and business-operational capabilities, with Casdin Capital’s financial resources, network and investment process, we will together add fuel to a now lit fire.”

Recommended AI News: The Neutrino Energy Group Transcends The Theoretical To Transform Practical Energy Use Worldwide

Eli Casdin, Managing Partner of Casdin Capital, stated, “This is not the first collaboration of this type we have entered into, having created a similar initiative in the bio-production space with BioLife Solutions. The accelerator model has successfully stimulated innovation there and we are confident that it will have an even bigger impact in the synthetic biology space and accelerate the growth of this emerging technology field.”

Recommended AI News: Brexit Is Driving British Citizens To Citizenship By Investment Programmes

Leave A Reply

Your email address will not be published.